Latest Regulatory Approval News

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

FIN Resources has completed the acquisition of the Cabin Lake Gold Project in Canada’s Northwest Territories, securing key permits and preparing for a fully funded drilling campaign starting in March 2026.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Basin Energy has executed a definitive agreement to sell its Marshall Uranium Project to Green Canada Corporation, securing upfront payments and retaining significant future upside through equity and buyback options.

Lunnon Metals reports a significant 49% increase in gold ounces at its Lady Herial deposit, now hosting 54,200 ounces, with mining operations underway and strong economic prospects supported by a binding Ore Purchase Agreement.

Clydesdale Bank, trading as Virgin Money, will transfer its banking business to Nationwide Building Society following High Court approval, marking a key step in their integration.

MinRex Resources Limited (ASX: MRR) has announced a definitive agreement to acquire 100% of Electrum Discovery Corp. (TSX-V: ELY) via a statutory Plan of Arrangement, creating a combined ASX-listed gold-copper exploration company with significant assets in Serbia and Australia.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Ramsay Health Care’s half-year results reveal a dramatic net profit rebound, driven by prior year impairments and solid growth in Australia and Europe. The company also announced a strategic acquisition and a proposed share distribution.